Starpharma is a clinical-stage biopharmaceutical company specializing in the development of dendrimer-based products across infectious disease, oncology and ophthalmology. Its proprietary dendrimer platform, DEP™ (Dendrimer Enhanced Products), enables precise molecular engineering to enhance drug delivery, targeting and safety profiles. The company’s lead product, VivaGel®, is a topical microbicide that has been approved in multiple markets for the treatment and prevention of bacterial vaginosis and is in clinical development for antiviral applications.
In addition to VivaGel, Starpharma is advancing pipeline candidates that leverage DEP technology to improve the performance of established and novel therapeutic agents. These include an antiviral nasal spray for respiratory viruses and investigational oncology conjugates designed to selectively deliver cytotoxic drugs to tumor cells. The adaptable nature of the dendrimer platform allows Starpharma to tailor its technology for diverse therapeutic areas.
Starpharma has forged strategic partnerships and licensing agreements with leading pharmaceutical companies to commercialize and co-develop DEP-enhanced products. Collaborations include deals with AstraZeneca and Mundipharma for support of antibacterial and oncology candidates, as well as academic and governmental research collaborations aimed at broadening the application of dendrimer technology in global health.
Founded in 2000 and headquartered in Melbourne, Australia, Starpharma serves markets in North America, Europe and Asia Pacific through its own operations and partner networks. The company is led by CEO Jackie Fairley, whose background in biopharmaceutical research and development has guided Starpharma’s growth from an early-stage innovator to a diversified clinical-stage company.
AI Generated. May Contain Errors.
